VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DGXQuest Diagnostics Incorporated
$256.35$28.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
DGX logo

Quest Diagnostics Incorporated

DGX
NYSE · Diagnostics & Lab Testing
$256.35
At close - Nov 17, 4:00 PM EST - USD
Market Cap$28.29B
P/E25.4x
52W High$263.19
Volume936.04K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Double Digit Growth Meets Valuation Skepticism

Quest Diagnostics delivered 10.0% year-over-year revenue growth to $3.1B in 2026Q3, with operating margin expanding to 15.5% and diluted EPS up 28.7%, suggesting the diagnostic franchise still retains meaningful pricing and test-mix leverage despite deceleration from the 15.2% peak in 2025Q2.

GrowthExpanding
ProfitabilityStrong
ValuationReview
TechnicalsStrong
Explore valuation models
MARKET ACTION

DGX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

12/12 Beats

EPS beat 12 of last 12 quarters

02

Valuation risk

-25% Peers

P/E is 25% below peer median

03

Market leadership

RS 86 · Leader

High momentum (Outperforming 86% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 22
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue reached $3.1B in 2026Q3 (10.0% growth) with gross margin stable at 33.6% — roughly 680 basis points above Labcorp's 26.8% — though SG&A held at 16.9% of revenue suggests limited incremental operating leverage from overhead.

Analyst Consensus-0.1% target
Hold(34 analysts)
13 Buy18 Hold3 Sell

The Bull Case

Upside Catalysts

Strong revenue and earnings growth

Quest Diagnostics reported higher sales and earnings in Q4 2025 and Q1 2026, with 9.2% YoY revenue growth and 13% adjusted EPS growth, driven by organic growth and productivity gains.

Positive 2026 financial guidance

The company issued 2026 guidance projecting US$11.70-US$11.82 billion in revenue and US$9.45-US$9.65 in diluted EPS, indicating confidence in continued growth.

Dividend increase

Quest Diagnostics raised its quarterly dividend, signaling strong cash flow and commitment to returning capital to shareholders.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
DGX+49.45%
S&P 500 (^GSPC)+7.21%
1-Year Return
DGX+39.50%
S&P 500 (^GSPC)+10.03%
3-Year Return
DGX+97.08%
S&P 500 (^GSPC)+58.77%
5-Year Return
DGX+83.92%
S&P 500 (^GSPC)+53.22%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
25.4x
Forward P/EExpansion
22.7x
EV/EBITDA100th %ile
15.0x
FCF YieldCash Flow
4.9%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
25.4x
19.6x
100th· High
EV/EBITDA
15.0x
12.0x
100th· High
Price/FCF
20.6x
14.4x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$128.83-49.7%
Base (Fair)$273.90+5.5%
Bull$505.97+97.4%
$128.83 Bear$273.90 Base$505.97 Bull
Current Market Price: $256.35
Trades at a 6.4% discount to Base DCF ($273.90)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$11.04B+11.8% YoY
Net income FY25
$992M+13.9% YoY
Free cash flow FY25
$1.36B+49.5% YoY
Operating margin FY25
14.5%+0.9 pts YoY
ROIC (FY25)8.8%
Avg ROIC 5Y10.6%
ROE (TTM)14.7%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate12/12 (100%)
Revenue Beat Rate12/12 (100%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 22, 2026
$3.00+4.5%
vs $2.87
$3.1B+1.5%
vs $3.1B
Q3 2026
Jul 23, 2026
$3.12+10.6%
vs $2.82
$3.0B+2.4%
vs $3.0B
Q2 2026
Apr 21, 2026
$2.50+5.5%
vs $2.37
$2.9B+2.3%
vs $2.8B
Q1 2026
Feb 10, 2026
$2.42+2.5%
vs $2.36
$2.8B+1.9%
vs $2.8B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
PRNewsWire·Nov 10, 2026
Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., Nov. 10, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on January 27, 2027, to shareholders of record of Quest Diagnostics common stock on January 12, 2027.

PRNewsWire·Nov 9, 2026
Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare Conference

SECAUCUS, N.J., Nov. 9, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Miami on Tuesday, December 1, 2026, at 2:10 p.m.

PRNewsWire·Nov 9, 2026
Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference in London

SECAUCUS, N.J., Nov. 9, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 8:30 a.m.

Zacks Investment Research·Oct 27, 2026
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Filtered for Quest Diagnostics IncorporatedMore Headlines
04

Compare before deciding

Benchmark DGX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Quest Diagnostics Incorporated (DGX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
DGX logoDGXQuest Diagnostics IncorporatedCurrent
$256.35$28.29B25.4311.78%9.53%14.66%1.22%
LH logoLHLabcorp Holdings Inc.
$368.24$30.2B29.937.25%6.88%11.52%0.78%
BIO logoBIOBio-Rad Laboratories, Inc.
$358.19$9.64B9.440.65%39.45%14.07%—
NEOG logoNEOGNeogen Corporation
$10.90$2.37B-42.36-2.71%-6.35%-2.68%—
QDEL logoQDELQuidelOrtho Corporation
$9.87$673.05M-1.84-1.89%-14.24%-20.13%—
MYRG logoMYRGMYR Group Inc.
$267.27$4.16B21.758.79%4.48%26.32%—

Compare DGX vs Peers

Quest Diagnostics Incorporated (DGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LH

Most directly comparable listed peer for DGX.

Scale Benchmark

vs UNH

Larger-name benchmark to compare DGX against a more recognizable public peer.

Peer Set

Compare Top 5

vs LH, BIO, NEOG, QDEL

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

DGX SEC Filings & Documents

Quest Diagnostics Incorporated (DGX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 22, 2026·SEC

Material company update

Oct 22, 2026·SEC

Material company update

Oct 6, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 23, 2026·SEC

FY 2026

Jul 23, 2026·SEC

FY 2026

Apr 22, 2026·SEC

Get notified when DGX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

DGX Frequently Asked Questions

Quest Diagnostics Incorporated (DGX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Quest Diagnostics Incorporated's revenue?

Quest Diagnostics Incorporated (DGX) reported $11.84B in revenue over the trailing twelve months. Revenue was $11.04B in fiscal year 2025. That is 583% more than the $1.62B of fiscal year 1996.

How fast is Quest Diagnostics Incorporated growing?

Quest Diagnostics Incorporated (DGX) grew revenue by 9.1% over the trailing twelve months, compared with the twelve months before.

Is DGX profitable?

Yes. Quest Diagnostics Incorporated (DGX) earned $1.13B in net income over the trailing twelve months (a 9.5% net margin).

Dividend & Returns
Does DGX pay dividends?

Yes. Quest Diagnostics Incorporated (DGX) pays a dividend that yields 1.22% at the current price, a moderate yield.

What is DGX's return on equity?

Quest Diagnostics Incorporated (DGX) had a return on equity (ROE) of 14.7% over the trailing twelve months. That is in line with the market's typical 10-15%.

What is Quest Diagnostics Incorporated's free cash flow?

Quest Diagnostics Incorporated (DGX) generated $1.38B in free cash flow over the trailing twelve months.

What if you invested $1,000 in DGX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →